Journal ArticleDOI
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
About:
This article is published in Yearbook of Obstetrics, Gynecology and Women's Health.The article was published on 2010-01-01. It has received 556 citations till now. The article focuses on the topics: Denosumab & Osteoporosis.read more
Citations
More filters
Journal ArticleDOI
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.
Salvatore L. Ruggiero,Thomas B. Dodson,John Fantasia,Reginald Goodday,Tara Aghaloo,Bhoomi Mehrotra,Felice O'Ryan +6 more
TL;DR: The American Association of Oral and Maxillofacial Surgeons (AAOMS) developed guidelines for medication-related osteonecrosis of the jaw (MRONJ) in 2007 and 2009 as mentioned in this paper.
Journal ArticleDOI
Osteoporosis: now and the future
TL;DR: Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation and the most promising novel treatments include denosumab, a monoclonal antibody for receptor activator of NF-κB ligand; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation.
Journal ArticleDOI
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou,Suzanne N Morin,Angela M. Cheung,Stephanie A. Atkinson,Jacques P. Brown,Sidney Feldman,David A. Hanley,Anthony B. Hodsman,Sophie A. Jamal,Stephanie M. Kaiser,Brent Kvern,Kerry Siminoski,William D. Leslie +12 more
TL;DR: There has been a paradigm shift in the prevention and treatment of osteoporosis and fractures, and the focus now is on preventing fragility fractures and their negative effects.
Journal ArticleDOI
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck,Allan Lipton,Jean-Jacques Body,Guenther G. Steger,Katia Tonkin,Richard De Boer,Mikhail Lichinitser,Yasuhiro Fujiwara,Denise A. Yardley,María Viniegra,Michelle Fan,Qi Jiang,Roger Dansey,Susie Jun,Ada Braun +14 more
TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Journal ArticleDOI
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
Samuel D Vasikaran,Samuel D Vasikaran,Richard Eastell,Olivier Bruyère,A. J. Foldes,P. Garnero,Andrea Griesmacher,Michael R. McClung,Howard A. Morris,Stuart L. Silverman,Tommaso Trenti,D. A. Wahl,Cyrus Cooper,Cyrus Cooper,John A. Kanis +14 more
TL;DR: BTM hold promise in fracture risk prediction and for monitoring treatment and Uncertainties over their clinical use can be in part resolved by adopting international reference standards.
References
More filters
Journal ArticleDOI
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings,Javier San Martin,Michael R. McClung,Ethel S. Siris,Richard Eastell,Ian R. Reid,Pierre D. Delmas,Holly B. Zoog,M. Austin,Andrea Wang,Stepan Kutilek,Silvano Adami,Jose R. Zanchetta,Cesar Libanati,Suresh Siddhanti,Claus Christiansen +15 more
TL;DR: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.